For Inhalation Use Only.

The recommended dose of Hypertonic saline solution for inhalation is one unit-dose vial 2 to 4 times a day, undiluted via a nebuliser.

PulmcoClear strength and dose should be individualised based on the status of the patient, age group and should be assessed at regular intervals of symptoms.

Prescribing PulmoClear by brand is the least expensive way of prescribing 3%, 6% and 7% Hypertonic Sodium Chloride Inhalation solution.

PulmoClear costs approximately 30% less than Nebusal & MucoClear, or prescribing Generic Hypertonic Sodium Chloride Inhalation solution.

Every Year NHS spends approximately more than £ 2m on hypertonic saline solution for inhalation. By switching to PulmoClear, NHS can save upto £ 500,000 a year.

In cases of cystic fibrosis, bronchiectasis, bronchiolitis; PulmoClear increases the mobilisation of secretions in the lower respiratory tract by osmotic effects.

PulmoClear prevents drying of bronchial mucous.

PulmoClear hypertonic saline solution for inhalation can be used with pneumatic or ultrasonic nebulisers.

For Inhalation Use Only.

The recommended dose of Hypertonic saline solution for inhalation is one unit-dose vial 2 to 4 times a day, undiluted via a nebuliser.

PulmcoClear strength and dose should be individualised based on the status of the patient, age group and should be assessed at regular intervals of symptoms.

Cystic Fibrosis (CF): Delivered following a bronchodilator, hypertonicsodium chloride 7% appears inexpensive and safe with no increasedinfection risk. A Cochrane review stated that there is sufficientevidence to recommend using hypertonic sodium chloride 7% inthose with CF (Wark 2009) (Elkins 2006).

It was found that Hypertonic Saline inhaled twice per day reduced episodes of chest infection and was linked to lung function andquality of life improvement, and better attendance at school or work.

Bronchiectasis: British Thoracic Society Guidelines for the treatment of non-CF bronchiectasis suggest that hypertonic sodium chloridemay be considered for use prior to airway clearance to increasesputum yield, reduce sputum viscosity and improve ease of expectoration (BTS July 2010).

Nebulized HS is a safe and potentially effective treatment of infantswith acute bronchiolitis.

In concentrations of 3-14%, hypertonic saline has been shown toimprove tracheobronchial clearance in patients with chronicbronchitis, CF, asthma and normal individuals.

Hypertonic saline resulted in an improvement in measures of mucociliary clearance over isotonic saline and cough alone (Riedler 1996; Robinson 1996; Robinson 1997; Robinson 1999).

Hypersensitivity to inhalation Sodium Chloride solution.

The solution should not be administered orally or parenterally.

Do not mix with other medications.

Single use only.

Strictly reserved to inhalation. Not for injection.

Follow the nebuliser manufacturer's instructions for use.